By Fineline Cube 
China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation system has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation highlights the potential of the system to address a significant unmet medical need in the treatment of moderate to severe asthma.
System Mechanism
The asthma cryoablation system is designed to treat moderate to severe asthma. The procedure involves using cryoablation to damage the vagus nerve in the lungs. By reducing the excessive release of acetylcholine—a key contributor to asthma symptoms—the system aims to decrease mucus secretion and provide therapeutic relief for asthma patients.-Fineline Info & Tech